Aldevron Recognized as a 2026 CDMO Leadership Awards Winner

April 14, 2026 / by Aldevron

Partner‑validated recognition reflecting real‑world collaboration and performance

Aldevron has been named a 2026 CDMO Leadership Awards Winner in the Small/Mid‑Size Cell & Gene Therapy category, based entirely on direct feedback from biopharma companies actively working with CDMOs.

The CDMO Leadership Awards are driven by verified evaluations from industry partners who have collaborated closely with CDMOs over the past 18–24 months. These insights capture real, day‑to‑day working experiences across active programs, offering an authentic perspective on what it is like to partner with a CDMO in practice.

For 2026, Aldevron was recognized across multiple areas that matter most to teams advancing complex therapies, including Analytical Services, Overall Staff, Project Management, Cultural Fit, Technology Use, and Scaling Support. Together, these categories reflect the strength of Aldevron’s teams and their ability to support partners through critical stages of cell and gene therapy development.

“This recognition is especially meaningful because of the signal of trust, confidence, and partnership this sends from our clients, which we strive to achieve and maintain every single day,” said Jennifer Meade, President of Aldevron. “It speaks to the dedication of our teams, their commitment to collaboration, and the care they bring to supporting complex cell and gene therapy programs as our partners work to make a real difference for patients.”

The 2026 CDMO Leadership Awards ceremony took place March 25 in New York City.

Learn more about the CDMO Leadership Awards at www.cmoleadershipawards.com.